Proposal from the Nomination Committee to the Extraordinary General Meeting in Bionor on 11 March 2016
(Oslo, Norway, 8 March 2016) On 12 February 2016, the Board of Directors of Bionor announced the receipt of a request from Lars Høie and certain other shareholders, who jointly hold approximately 30 per cent of the share capital in the company, that an extraordinary general meeting be held for the election of a new Board of Directors of the company.
As a result of this request, the Board of Directors has called for an extraordinary general meeting in Oslo on 11 March 2016 at 12:00 CET with the purpose of electing a new Board of Directors.
A full board composition proposal from the Nomination Committee and CVs for the proposed new Chairman and Board Members are attached this announcement.
The unanimous proposal from the Nomination Committee suggests the following Board composition following the extraordinary general meeting on 11 March 2016:
- Per Thoresen as newly elected Chairman of the Board
- Lars H. Høie as new Board Member
- Jerome B. Zeldis as re-elected Board Member
- Benedicte Fossum as re-elected Board Member
- Thomas Hofstaetter as re-elected Board Member
- Kirsten Drejer as re-elected Board Member
- Ingrid Leisner as new Board Member
The further supplement of an eighth Board Member will be considered before the annual general meeting on 21 April 2016.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
David Horn Solomon, President and CEO, +45 22 20 63 00, email@example.com
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, firstname.lastname@example.org
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The Company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the Company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.